SFX by Ex Libris Inc.

Title:	Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Source:	Nature Biotechnology [1087-0156] Wu, Chengbin yr:2007

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Boker, A. "Biologicals in the treatment of psoriasis." Current opinion in investigational drugs 8.11 (2007): 939-46.
description	2.	Schmidt, F R R. "Recombinant expression systems in the pharmaceutical industry." Applied microbiology and biotechnology 65.4 (2004): 363-72.
description	3.	Strand, V. "Biologic therapies in rheumatology: Lessons learned, future directions." Nature reviews. Drug discovery 6.1 (2007): 75-92.
description	4.	Robertson, Susan E E. "Expression and alternative processing of IL-18 in human neutrophils." European journal of immunology 36.3 (2006): 722-31.
description	5.	Kontermann, Roland E. "Recombinant bispecific antibodies for cancer therapy." Acta pharmacologica Sinica (monthly) 26.1 (2005): 1-9.
description	6.	Wittig, Bianca Maria M. "CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases." Current opinion in investigational drugs 8.11 (2007): 947-954.
description	7.	Andersen, D. "Recombinant protein expression for therapeutic applications." Current opinion in biotechnology 13.2 (2002): 117-123.
description	8.	Laffly, E. "Monoclonal and recombinant antibodies, 30 years after..." Human Antibodies 14.1-2 (2005): 33-55.
description	9.	Jana, S. "Strategies for efficient production of heterologous proteins in Escherichia coli." Applied microbiology and biotechnology 67.3 (2005): 289-298.
description	10.	Ham, T.S. S. "A tightly regulated inducible expression system utilizing the fim inversion recombination switch." Biotechnology and bioengineering 94.1 (2006): 1-4.
description	11.	McVeigh, Andrew M. "TNF inhibitors for ankylosing spondylitis in the real world." Rheumatology international 28.2 (2007): 199-200.
description	12.	Saurat, JH. "Adalimumab treatment is associated with more rapid improvement in psoriasis versus methotrexate and versus placebo: results from the CHAMPION study." British journal of dermatology 157.Suppl 1 (2007): 9-9.
description	13.	Gartlehner, G. "The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis." The Journal of rheumatology 33.12 (2006): 2398-2408.
description	14.	Furst, D. E. "Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007." Annals of the rheumatic diseases 66.Suppl (2007): 2-22.
description	15.	Wozel, G. "[Systemic psoriasis therapy - the next step. Adalimumab]." Hautarzt 58.6 (2007): 515-8.
description	16.	Wang, W. "Antibody structure, instability, and formulation." Journal of pharmaceutical sciences 96.1 (2006): 1-26.
description	17.	Schmidt, M Alexander A. "Sweet new world: glycoproteins in bacterial pathogens." Trends in Microbiology 11.12 (2004): 554-61.
description	18.	Campa, A. "A novel function of serum amyloid A: A potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 by human blood neutrophil." Biochemical and biophysical research communications 268.2 (2000): 405-408.
description	19.	"Research and Markets Adds Report : Powering Up: Are Computer Games Changing Our Lives?" Telecommunications reports, wireless (2008).
description	20.	Grosse-Hovest, L. "Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing." Proceedings of the National Academy of Sciences of the United States of America 101.18 (2004): 6858-6863.